Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease.
Maeve A O'ReillyRobin SandersonWilliam WilsonSunil IyengarJonathan LambertRory McCullochToby Andrew Eyrenull nullPublished in: British journal of haematology (2022)